Faeth Therapeutics FTH Income Statement (2020-2026)

NASDAQ FTH
$32.10 -1.01 (-3.05%)
At close: Aug 20, 2026 · 4:00 PM EDT
Income Statement Mar2020 Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026 Jun2026
Shares Outstanding (Entity) (Quarter)
30.59M30.61M30.68M30.72M30.72M30.76M30.97M26.58M25.00M25.03M25.07M25.12M25.15M25.18M25.21M1.26M1.26M1.26M1.34M5.64M
Operating items
Research & Development (Quarter)
6.44M5.96M7.46M6.39M9.19M7.34M5.20M4.78M3.82M4.49M4.92M4.58M4.64M4.49M3.73M2.53M2.54M2.17M17.96M9.18M
Selling, General & Administrative (Quarter)
3.87M3.46M5.03M4.32M4.75M5.70M5.80M5.39M3.92M3.65M3.81M3.20M3.19M2.83M3.55M2.67M2.31M2.79M19.71M9.21M
Other Operating Expenses (Quarter)
0.02M-0.10M-0.19M-0.01M0.95M0.02M-0.04M-0.00M132.96M
Operating Expenses (Quarter)
10.32M9.41M12.49M10.71M13.94M13.05M11.01M10.18M7.74M8.14M8.73M7.79M7.82M8.27M7.27M5.21M4.85M4.96M170.63M18.39M
Operating Income (Quarter)
-10.32M-9.41M-12.49M-10.71M-13.94M-13.05M-11.01M-10.18M-7.74M-8.14M-8.73M-7.79M-7.82M-8.27M-7.27M-5.21M-4.85M-4.96M-170.63M-18.39M
EBIT (Quarter)
-10.32M-9.41M-12.49M-10.71M-13.94M-13.05M-11.01M-10.18M-7.74M-8.14M-8.73M-7.79M-7.82M-8.27M-7.27M-5.21M-4.85M-4.96M-170.63M-18.39M
Non-operating items
Interest & Investment Income (Quarter)
0.28M0.87M-0.57M-0.31M0.01M0.61M0.18M0.27M0.15M3.02M0.07M0.04M0.11M2.33M0.39M-0.01M0.01M0.22M0.39M2.26M
Other Non Operating Income (Quarter)
0.57M0.01M0.02M0.00M0.01M0.07M-0.23M-0.07M-0.00M-0.00M0.02M-0.00M-0.00M-0.00M0.12M
Net income details
EBT (Quarter)
-24.84M-8.85M-13.30M-11.20M-20.75M-12.23M-11.24M-12.13M-9.58M-6.78M-9.12M-11.88M-11.41M-5.96M-7.36M-7.54M-6.74M-3.45M-182.39M-22.61M
Profit After Tax (Quarter)
-9.69M-9.37M-12.40M-10.54M-13.42M-11.36M-10.18M-9.39M-7.12M-8.02M-7.99M-7.14M-7.15M-7.99M-6.86M-4.94M-4.56M-4.73M-170.26M-16.05M
Income from Continuing Operations (Quarter)
-24.84M-8.85M-13.30M-11.20M-20.75M-12.23M-11.24M-12.13M-9.58M-6.78M-9.12M-11.88M-11.41M-5.96M-7.36M-7.54M-6.74M-3.45M-182.39M-22.61M
Consolidated Net Income (Quarter)
-24.84M-8.85M-13.30M-11.20M-20.75M-12.23M-11.24M-12.13M-9.58M-6.78M-9.12M-11.88M-11.41M-5.96M-7.36M-7.54M-6.74M-3.45M-182.39M-22.61M
Income towards Parent Company (Quarter)
-24.84M-8.85M-13.30M-11.20M-20.75M-12.23M-11.24M-12.13M-9.58M-6.78M-9.12M-11.88M-11.41M-5.96M-7.36M-7.54M-6.74M-3.45M-182.39M-22.61M
Preferred Dividend Payments (Quarter)
Net Income towards Common Stockholders (Quarter)
-9.69M-9.37M-12.40M-10.54M-13.42M-12.23M-10.18M-9.39M-7.12M-7.41M-7.99M-7.14M-7.25M-7.77M-6.86M-4.94M-4.57M-4.72M-170.24M-16.01M
Additional items
EPS (Basic) (Quarter)
-0.32-0.34-0.40-0.34-0.44-0.40-0.33-0.31-0.28-0.27-0.32-0.28-0.29-0.31-0.27-3.91-3.62-3.74-131.45-2.84
EPS (Diluted) (Quarter)
-0.32-0.34-0.40-0.34-0.44-0.40-0.33-0.31-0.28-0.27-0.32-0.28-0.29-0.31-0.27-3.91-3.62-3.74-131.45-2.84
Shares Outstanding (Quarter)
30.59M27.71M30.65M30.70M30.72M30.70M30.87M30.51M25.51M27.95M25.05M25.10M25.15M25.12M25.19M1.26M1.26M1.26M1.30M5.64M
Shares Outstanding (Diluted) (Quarter)
30.59M27.71M30.65M30.70M30.72M30.70M30.87M30.51M25.51M27.95M25.05M25.10M25.15M25.12M25.19M1.26M1.26M1.26M1.30M5.64M
EBITDA (Quarter)
-10.32M-9.41M-12.49M-10.71M-13.94M-13.05M-11.01M-10.18M-7.74M-8.14M-8.73M-7.79M-7.82M-8.27M-7.27M-5.21M-4.85M-4.96M-170.63M-18.39M
Interest Expenses (Quarter)
14.80M0.31M0.24M0.17M6.82M-0.21M0.41M2.23M1.99M1.66M0.46M4.14M3.70M0.02M0.48M2.32M1.90M-1.29M12.15M6.48M